Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Kinnate Biopharma Inc. (KNTE : NSDQ)
 
 • Company Description   
Kinnate Biopharma Inc. is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate Biopharma Inc. is based in SAN FRANCISCO, California.

Number of Employees: 61

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.99 Daily Weekly Monthly
20 Day Moving Average: 157,333 shares
Shares Outstanding: 43.97 (millions)
Market Capitalization: $439.32 (millions)
Beta: 2.51
52 Week High: $26.05
52 Week Low: $7.29
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 17.39% 32.22%
12 Week 16.84% 28.46%
Year To Date -43.62% -31.12%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
103 Montgomery Street Suite 150
-
San Francisco,CA 94129
USA
ph: 858-299-4699
fax: -
investors@kinnate.com http://www.kinnate.com
 
 • General Corporate Information   
Officers
Nima Farzan - President and Chief Executive Officer
Dean Mitchell - Chairman
Neha Krishnamohan - Chief Financial Officer and Executive Vice Preside
Melissa Epperly - Director
Keith Flaherty - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 49705R105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 43.97
Most Recent Split Date: (:1)
Beta: 2.51
Market Capitalization: $439.32 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.55 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.49
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -52.50%
vs. Previous Quarter: -1.67%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -30.12
12/31/21 - -25.64
09/30/21 - -20.98
ROA
03/31/22 - -26.34
12/31/21 - -23.25
09/30/21 - -19.60
Current Ratio
03/31/22 - 20.15
12/31/21 - 20.88
09/30/21 - 25.31
Quick Ratio
03/31/22 - 20.15
12/31/21 - 20.88
09/30/21 - 25.31
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.73
12/31/21 - 7.31
09/30/21 - 7.81
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 10.58
12/31/21 - 9.87
09/30/21 - 9.31
 

Powered by Zacks Investment Research ©